BRPI0415111A - composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético - Google Patents

composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético

Info

Publication number
BRPI0415111A
BRPI0415111A BRPI0415111-9A BRPI0415111A BRPI0415111A BR PI0415111 A BRPI0415111 A BR PI0415111A BR PI0415111 A BRPI0415111 A BR PI0415111A BR PI0415111 A BRPI0415111 A BR PI0415111A
Authority
BR
Brazil
Prior art keywords
fluoroanilino
methyl
phenylacetic acid
chloro
pharmaceutical composition
Prior art date
Application number
BRPI0415111-9A
Other languages
English (en)
Inventor
Rose-Marie Dannenfelser
Vivian Christine Georgousis
Maha Y Khaled
Tarun S Patel
Joseph Sikora
Barbara Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0415111A publication Critical patent/BRPI0415111A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA QUE COMPREENDE O áCIDO 5-METIL-2-(2<39>-CLORO-6<39>-FLUOROANILINO) FENILACéTICO". A presente invenção refere-se a uma composição para o tratamento de uma doença ou condição mediada pela ciclooxigenase-2 compreendendo o ácido 5-metil-2-(2<39>-cloro-6<39>-fluoroanilino) fenilacético ou um sal farmaceuticamente aceitável, preferivelmente o sal de potássio do mesmo, adequado para administração parenteral, e a um método para o tratamento O de uma doença ou condição mediada pela ciclooxigenase-2 em um ser humano ou um animal, que esteja necessitando de tal tratamento, pela administração parenteral do ácido 5-metil-2-(2<39>-cloro-6<39>-fluoroanilino) fenilacético ou de um sal farmaceuticamente aceitável do mesmo, preferivelmente o sal de potássio do mesmo.
BRPI0415111-9A 2003-10-08 2004-10-07 composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético BRPI0415111A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50945903P 2003-10-08 2003-10-08
PCT/EP2004/011223 WO2005037266A1 (en) 2003-10-08 2004-10-07 Pharmaceutical composition comprising 5-methyl-2-(2’-chloro-6’-fluoroanilino)phenylacetic acid

Publications (1)

Publication Number Publication Date
BRPI0415111A true BRPI0415111A (pt) 2006-11-28

Family

ID=34465108

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415111-9A BRPI0415111A (pt) 2003-10-08 2004-10-07 composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético

Country Status (9)

Country Link
US (2) US20070123593A1 (pt)
EP (1) EP1673079A1 (pt)
JP (1) JP2007508263A (pt)
CN (1) CN1897929A (pt)
AU (1) AU2004281520B2 (pt)
BR (1) BRPI0415111A (pt)
CA (1) CA2541265A1 (pt)
MX (1) MXPA06003929A (pt)
WO (1) WO2005037266A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123800A2 (en) * 2006-04-03 2007-11-01 Nutramax Laboratories, Inc. Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ATE279920T1 (de) * 2000-12-28 2004-11-15 Fresenius Kabi Austria Gmbh Stabile infusionslösung von diclofenac-salzen, deren herstellung und verwendung
BR0210104A (pt) * 2001-05-31 2004-06-08 Pharmacia Corp Composição inibidora seletiva de ciclooxigenase-2 permeável à pele
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid

Also Published As

Publication number Publication date
US20070123593A1 (en) 2007-05-31
US20080287543A1 (en) 2008-11-20
EP1673079A1 (en) 2006-06-28
CN1897929A (zh) 2007-01-17
AU2004281520A1 (en) 2005-04-28
MXPA06003929A (es) 2006-07-05
CA2541265A1 (en) 2005-04-28
AU2004281520B2 (en) 2009-01-08
WO2005037266A1 (en) 2005-04-28
JP2007508263A (ja) 2007-04-05

Similar Documents

Publication Publication Date Title
NO20084199L (no) Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
BRPI0416796A (pt) compostos orgánicos
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
PA8603201A1 (es) Procedimiento y composiciones farmaceuticas para el tratamiento de arterosclerosis, dislipidemias y afecciones relacionadas
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
Jadav et al. Comparison of antiinflammatory activity of serratiopeptidase and diclofenac in albino rats
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
HK1087336A1 (en) Pharmaceutical composition comprising lumiracoxib
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
TW200833367A (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals
BR0308316A (pt) Sais de nateglinida
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
HUP0301128A2 (hu) 5-Metil-2-(2&#39;-kloro-6&#39;-fluoranilino)-fenilecetsavat tartalmazó gyógyszerkészítmények ciklooxigenáz-2-vel kapcsolatos betegségek kezelésére és alkalmazásuk
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
BRPI0415111A (pt) composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético
EA200401303A1 (ru) Лекарственные средства, содержащие стероиды и новое антихолинергическое средство
RU2353358C2 (ru) Производные прегабалина для лечения приливов
BR0318201A (pt) regime de dosagem de fármaco antiinflamatório não-esteroidal
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.
WO2007144889A3 (en) Treatment of neurofibromatosis
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
TW200600094A (en) Pharmaceutical compositions for prevention or treatment of disorders of lipid metabolism

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.